Neurokinin-1 Receptor Antagonists

Known as: Receptor Blockers, Neuroleukin-1, Receptor Antagonists, Neurokinin-1, Neurokinin 1 Receptor Antagonists 
Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.
National Institutes of Health

Related topics

Related topics

28 relations

Narrower (24)

AZD 2738AZD 8081CAM 4515CI 1021
(More)
In Bloodaspects of radiation effectschemical synthesisstandards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.
The tachykinins, exemplified by substance P, are one of the most intensively studied neuropeptide families. They comprise a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Osteosarcoma is a highly malignant bone tumor in children and adolescents. Aprepitant is a selective high‑affinity antagonist of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2013
Review
2013
Safety of neurokinin-1 receptor antagonists.
INTRODUCTION The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.
A screening of conformationally constrained aromatic amino acids as base cores for the preparation of new NK1 receptor… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Is this relevant?
2008
2008
Behavioral and Pharmacological Validation of the Gerbil Forced-Swim Test: Effects of Neurokinin-1 Receptor Antagonists
Several studies have suggested that neurokinin-1 (NK1) receptor antagonists may have therapeutic potential as novel… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2007
Review
2007
Muscarinic receptor antagonists for overactive bladder.
Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually… (More)
Is this relevant?
2007
2007
Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Based upon animal experiments and early clinical trials, neurokinin-1 receptor antagonists showed promise as novel… (More)
Is this relevant?
2007
2007
Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception.
BACKGROUND Neurokinins (e.g., substance P) contribute to pain transmission in the central nervous system, peripheral neurogenic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2003
2003
Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury.
Previously, we have shown that primary afferent sensory neurons are necessary for disease activity in T cell-mediated immune… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
1995
1995
Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus.
Octreotide, a somatostatin analogue that inhibits the release of most gut peptides, hastens the resolution of experimental… (More)
Is this relevant?